| 1 |
NCT02868268 |
Recruiting |
Neuroblastoma Precision Trial |
|
- Other: Gene panel sequencing of tumor specimens
|
Observational |
|
- New Approaches to Neuroblastoma Therapy Consortium
- Children's Hospital Los Angeles
- EVAN Foundation
- (and 3 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Identify genomic alterations, whether targetable alterations are present and within 4 defined NBL subgroups or outside of these 4 defined NBL subgroups. Identify presence/absence of immunologic biomarkers common to NBL.
- How many subjects are biopsied or provide available tumor that is found to be adequate for gene panel sequencing and produces a clinical report
- How many patients with bone marrow aspirates performed that contain < 30% tumor cells are able to be enriched and genetic alterations identified
|
90 |
All |
1 Year to 30 Years (Child, Adult) |
NCT02868268 |
N2015-01 |
|
August 2016 |
July 2018 |
December 2018 |
August 16, 2016 |
January 19, 2018 |
|
- Children's Hospital Los Angeles
Los Angeles, California, United States - Lucile Packard Children's Hospital at Stanford University Medical Center
Palo Alto, California, United States - UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States - (and 9 more...)
|
| 2 |
NCT03363373 |
Recruiting |
Naxitamab for Neuroblastoma With Osteomedullary Disease |
|
- Biological: GM-CSF + hu3F8
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Response rate during Naxitamab treatment
- Incidence of adverse events and serious adverse events
- Duration of Response (DoR)
- (and 11 more...)
|
37 |
All |
1 Year and older (Child, Adult, Senior) |
NCT03363373 |
201 |
|
April 2018 |
December 2020 |
December 2023 |
December 6, 2017 |
April 17, 2018 |
|
- Childrens Hospital Los Angeles
Los Angeles, California, United States - University of Florida
Gainesville, Florida, United States - Riley Hospital for Children
Indianapolis, Indiana, United States - (and 6 more...)
|
| 3 |
NCT02573896 |
Not yet recruiting |
Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells |
|
- Drug: Ch14.18
- Biological: NK Cells
- Drug: Lenalidomide
|
Interventional |
Phase 1 |
- New Approaches to Neuroblastoma Therapy Consortium
- Nationwide Children's Hospital
- United Therapeutics
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Feasibility of expanding NK cells from neuroblastoma patients and cryopreserving, shipping, and infusing multiple doses of NK cells.
- Determination of the Maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of autologous expanded NK cells
- Toxicity (Per Patient)
- Evaluation of Clinical Response (Per Patient)
|
24 |
All |
1 Month to 30 Years (Child, Adult) |
NCT02573896 |
NANT 2013-01 |
|
May 2018 |
October 2020 |
April 2021 |
October 12, 2015 |
April 11, 2018 |
|
- Children's Hospital Los Angeles
Los Angeles, California, United States - Lucille Salter Packer Children's Hospital, Stanford University
Palo Alto, California, United States - UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States - (and 10 more...)
|
| 4 |
NCT02615106 |
Recruiting |
Anti-angiogenetic Therapy With Radiotherapy for Pediatric Neuroblastoma |
|
- Drug: Endostar
- Radiation: 21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor
|
Interventional |
Phase 2 |
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
- Progression free survival(PFS)
- Overall survival (OS)
- Objective response rate (ORR)
|
60 |
All |
Child, Adult, Senior |
NCT02615106 |
SanghaiXinhua-001 |
|
November 2015 |
November 2017 |
November 2018 |
November 25, 2015 |
June 14, 2016 |
|
- The Department of Radiation Oncology, Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai, China
|
| 5 |
NCT03294954 |
Not yet recruiting |
GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma |
|
- Genetic: GINAKIT Cells
- Drug: Cyclophosphamide
- Drug: Fludarabine
|
Interventional |
Phase 1 |
- Baylor College of Medicine
- Center for Cell and Gene Therapy, Baylor College of Medicine
- Texas Children's Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of patients with dose limiting toxicity
- Disease free survival
|
24 |
All |
1 Year to 21 Years (Child, Adult) |
NCT03294954 |
GINAKIT2 |
GINAKIT2 |
January 15, 2019 |
February 15, 2020 |
January 15, 2035 |
September 27, 2017 |
October 6, 2017 |
|
- Texas Children's Hospital
Houston, Texas, United States
|
| 6 |
NCT02641314 |
Recruiting |
Metronomic Treatment in Children and Adolescents With Recurrent or Progressive High Risk Neuroblastoma |
|
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- non-inferiority of EFS compared to historical control group
- disease control rate at 6 months
- Overall survival
- (and 5 more...)
|
26 |
All |
2 Years to 20 Years (Child, Adult) |
NCT02641314 |
Uni-Koeln-1495
2011-004593-29 |
METRO-NB2012 |
October 2016 |
October 2018 |
March 2020 |
December 29, 2015 |
October 25, 2016 |
|
- University of Cologne; Dept. Ped. Oncology
Cologne, Germany
|
| 7 |
NCT02743429 |
Recruiting |
Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma |
|
|
Interventional |
Phase 2 |
- University Medicine Greifswald
- Children's Cancer Research Institute, Austria
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Anti-tumour activity of ch14.18/CHO continuous infusion
- Progression-Free Survival
- Safety and tolerability
- (and 12 more...)
|
40 |
All |
1 Year to 21 Years (Child, Adult) |
NCT02743429 |
APN311-304 |
|
March 2015 |
December 2017 |
June 2020 |
April 19, 2016 |
November 9, 2016 |
|
- University Medicine Greifswald
Greifswald, Germany
|
| 8 |
NCT02075177 |
Available |
Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma |
- Recurrent Neuroblastoma
- Neuroblastoma
|
- Drug: Fenretinide Lym-X-Sorb Oral Powder
- Drug: Ketoconazole
|
Expanded Access |
|
- South Plains Oncology Consortium
|
Other |
|
|
|
All |
Child, Adult, Senior |
NCT02075177 |
SPOC-2014-001 |
|
|
|
|
March 3, 2014 |
May 24, 2017 |
|
- University of Oklahoma Health Science Center
Oklahoma City, Oklahoma, United States - UT Southwestern Medical Center
Dallas, Texas, United States - Cook Children's Hospital
Fort Worth, Texas, United States
|
| 9 |
NCT01308905 |
Recruiting |
Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography (FLT-PET) |
|
|
Interventional |
Not Applicable |
- Barbara Ann Karmanos Cancer Institute
- Children's Hospital of Michigan
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- To determine whether 18F-FLT-PET is a sensitive tool to image neuroblastoma.
- To evaluate the utility of FLT-PET in early assessment of patient response to treatment.
- To evaluate the utility of FLT-PET in early assessment of patient response to
|
50 |
All |
up to 21 Years (Child, Adult) |
NCT01308905 |
WSU 2009-031 |
|
February 2011 |
February 2018 |
February 2018 |
March 4, 2011 |
April 6, 2017 |
|
- Children's Hospital of Michigan
Detroit, Michigan, United States
|
| 10 |
NCT03373097 |
Recruiting |
Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma |
- Neuroblastoma
- Neuroblastoma Recurrent
|
|
Interventional |
Phase 1
Phase 2 |
- Bambino Gesù Hospital and Research Institute
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Phase I - Identification of the dose limiting toxicity (DLT)
- Phase II - Antitumor effect
- In vivo persistence/expansion of infused CAR T cell
- (and 6 more...)
|
42 |
All |
12 Months to 18 Years (Child, Adult) |
NCT03373097 |
GD2CAR01 |
|
December 2017 |
December 2024 |
December 2027 |
December 14, 2017 |
December 27, 2017 |
|
- Ospedale Pediatrico Bambino Gesù
Roma, Italy
|
| 11 |
NCT03242603 |
Recruiting |
Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells |
|
- Biological: Anti-GD2 in combination with NK cells
|
Interventional |
Phase 1
Phase 2 |
- National University Hospital, Singapore
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To measure tumor response after infusion of expanded activated haploidentical NK cells with anti-GD2. Response will be assessed as defined by Revised International Neuroblastoma Response Criteria 2017.
- To measure the numbers of infused NK cells in peripheral blood at specific time-points after NK cell infusion
- To measure cytokine levels in plasma at specific time-points after NK cell infusion
|
5 |
All |
6 Months to 25 Years (Child, Adult) |
NCT03242603 |
NKEXPGD2 |
NKEXPGD2 |
October 3, 2017 |
August 15, 2019 |
August 15, 2020 |
August 8, 2017 |
March 30, 2018 |
|
- National University Hospital
Singapore, Singapore
|
| 12 |
NCT02679144 |
Recruiting |
Neuroblastoma Maintenance Therapy Trial |
|
- Drug: Difluoromethylornithine (DFMO)
|
Interventional |
Phase 2 |
- Giselle Sholler
- KC Pharma
- Beat NB Cancer Foundation
- (and 2 more...)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of participants with event free survival (EFS) during study.
- Length of time that participants experience Overall Survival (OS)
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
- (and 4 more...)
|
258 |
All |
1 Year to 30 Years (Child, Adult) |
NCT02679144 |
NMTRC014 |
NMTT |
February 2016 |
February 2020 |
February 2025 |
February 10, 2016 |
February 15, 2018 |
|
- University of Alabama, Children's of Alabama
Birmingham, Alabama, United States - Phoenix Children's Hospital
Phoenix, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 28 more...)
|
| 13 |
NCT01704716 |
Recruiting |
High Risk Neuroblastoma Study 1.7 of SIOP-Europe (SIOPEN) |
|
- Drug: Vincristine
- Drug: Aldesleukin
- Drug: ch14.18/CHO
- (and 8 more...)
|
Interventional |
Phase 3 |
- St. Anna Kinderkrebsforschung
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event Free Survival (R1: MAT therapy)
- Event Free Survival (R4: immunotherapy)
- Complete metastatic response (R3: Induction therapy)
- Event free survival (R3: Induction therapy)
|
2700 |
All |
1 Month to 21 Years (Child, Adult) |
NCT01704716 |
HR-NBL-1.7 / SIOPEN |
|
February 2002 |
September 2017 |
September 2017 |
October 11, 2012 |
September 27, 2016 |
|
- Sydney Children's Hospital
Sydney, Australia - St. Anna Kinderspital
Vienna, Austra, Austria - Univ.-Klinik für Kinder- und Jugendheilkunde Graz
Graz, Austria - (and 113 more...)
|
| 14 |
NCT02298348 |
Recruiting |
Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma |
|
- Drug: Sorafenib
- Drug: Cyclophosphamide
- Drug: Topotecan
|
Interventional |
Phase 1 |
- New Approaches to Neuroblastoma Therapy Consortium
- University of California, San Francisco
- Children's Hospital Los Angeles
- (and 10 more...)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The maximum tolerated dose of sorafenib given twice each day when given in combination with cyclophosphamide/topotecan for 5 days
- The number and types of toxicities of sorafenib when administered in combination with cyclophosphamide and topotecan.
|
18 |
All |
up to 30 Years (Child, Adult) |
NCT02298348 |
NANT 2013-02 |
N2013-02 |
April 2015 |
June 2018 |
January 2019 |
November 21, 2014 |
January 19, 2018 |
|
- Children's Hospital Los Angeles
Los Angeles, California, United States - Lucille Salter Packer Children's Hospital, Stanford University
Palo Alto, California, United States - UCSF Comprehensive Cancer Center
San Francisco, California, United States - (and 10 more...)
|
| 15 |
NCT02605421 |
Recruiting |
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma |
|
- Drug: Thiotepa
- Drug: Cyclophosphamide
- Drug: Melphalan
- (and 4 more...)
|
Interventional |
Phase 2 |
- Masonic Cancer Center, University of Minnesota
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival
- Time to Engraftment
- Relapse
- Overall Survival
|
12 |
All |
up to 30 Years (Child, Adult) |
NCT02605421 |
2015LS108 |
|
June 2016 |
January 2020 |
January 2023 |
November 16, 2015 |
December 5, 2017 |
|
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
|
| 16 |
NCT01857934 |
Recruiting |
Therapy for Children With Advanced Stage Neuroblastoma |
|
- Drug: cyclophosphamide
- Drug: topotecan
- Biological: hu14.18K322A
- (and 18 more...)
|
Interventional |
Phase 2 |
- St. Jude Children's Research Hospital
- Cookies for Kids' Cancer
- CURE Childhood Cancer, Inc.
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with complete or partial response
- Event-free survival (EFS)
- Feasibility of delivering hu14.18K322A to 6 cycles of induction therapy
- (and 3 more...)
|
210 |
All |
up to 18 Years (Child, Adult) |
NCT01857934 |
NB2012
NCI-2013-00034 |
|
July 5, 2013 |
January 2021 |
July 2021 |
May 20, 2013 |
December 20, 2017 |
|
- St. Jude Children's Research Hospital
Memphis, Tennessee, United States
|
| 17 |
NCT02998983 |
Recruiting |
Racotumomab in Patients With High-risk Neuroblastoma |
|
|
Interventional |
Phase 2 |
- Laboratorio Elea S.A.C.I.F. y A.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants who elicit an immune response to a one-year immunization schedule of racotumomab in a cohort study of patients with high-risk neuroblastoma.
- Number of participants in whom minimally disseminated disease in the bone marrow decreases or disappears with a one-year immunization schedule of racotumomab compared to baseline values at study entry.
- Number of Participants With Treatment-Related Adverse Events as assessed by CTCAE v4.0 after a one-year immunization schedule of racotumomab when administered alone or together with onco-specific metronomic chemotherapy therapy.
- Pattern of expression of N-Glycolyl-GM3 gangliosides in tumor samples obtained at disease diagnosis and during follow up if available.
|
39 |
All |
1 Year to 12 Years (Child) |
NCT02998983 |
AR-RACO-2-16 |
|
November 2016 |
November 2019 |
June 2020 |
December 21, 2016 |
September 12, 2017 |
|
- Hospital Universitario Austral
Pilar, Buenos Aires, Argentina - Prof. Dr. J. P. Garrahan National Children's Hospital
Buenos Aires, Argentina
|
| 18 |
NCT02919046 |
Recruiting |
Study Evaluating the Efficacy and Safety With CAR-T for Relapsed or Refractory Neuroblastoma in Children |
- Relapsed or Refractory Neuroblastoma
|
- Biological: GD2-targeted CAR-T cells
|
Interventional |
Not Applicable |
- Sinobioway Cell Therapy Co., Ltd.
- Nanjing Children's Hospital
- Children's Hospital of Fudan University
|
Industry / Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The overall efficiency of patients with neuroblastoma after autologous CAR-T cell therapy
- Progression free survival
- Overall survival
- (and 2 more...)
|
22 |
All |
1 Year to 14 Years (Child) |
NCT02919046 |
WM-CART-07 |
|
September 2016 |
September 2020 |
September 2020 |
September 29, 2016 |
March 14, 2017 |
|
- Nanjing Children's Hospital
Nanjing, Jiangsu, China - Children's Hospital of Fudan University
Shanghai, Shanghai, China
|
| 19 |
NCT02163356 |
Recruiting |
Fenretinide Lym-X-Sorb + Ketoconazole + Vincristine for Recurrent or Resistant Neuroblastoma |
- Recurrent Neuroblastoma
- Neuroblastoma
|
- Drug: Fenretinide/LXS Oral Powder
- Drug: Ketoconazole
- Drug: Vincristine
|
Interventional |
Phase 1 |
- South Plains Oncology Consortium
- EVAN Foundation
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose
- Side effect profile of drug combination
- Assess plasma pharmacokinetics of fenretinide
- Disease response
|
42 |
All |
up to 30 Years (Child, Adult) |
NCT02163356 |
SPOC-2013-001 |
SPOC2013-001 |
May 2014 |
May 2018 |
May 2018 |
June 13, 2014 |
May 24, 2017 |
|
- The University of Chicago Medicine Comer Children's
Chicago, Illinois, United States - UT Southwestern Medical Center
Dallas, Texas, United States - Cook Children's Hospital
Fort Worth, Texas, United States - Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
| 20 |
NCT03033303 |
Recruiting |
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma |
|
- Biological: Hu3F8
- Drug: GM-CSF
- Drug: Isotretinoin
|
Interventional |
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- Y-mAbs Therapeutics
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- relapse-free survival (RFS)
|
59 |
All |
Child, Adult, Senior |
NCT03033303 |
16-1643 |
|
January 23, 2017 |
June 2022 |
June 2022 |
January 26, 2017 |
December 27, 2017 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
| 21 |
NCT02630043 |
Recruiting |
Trial of Tolcapone With Oxaliplatin for Neuroblastoma |
|
- Drug: Tolcapone
- Drug: Oxaliplatin
|
Interventional |
Phase 1 |
- Giselle Sholler
- Spectrum Health Hospitals
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
- Determine the Overall Response Rate (ORR) of Participants using RECIST criteria
- Determine the Progression Free Survival (PFS) of Participants using days until progression
- (and 5 more...)
|
21 |
All |
up to 21 Years (Child, Adult) |
NCT02630043 |
NMTRC011 |
|
December 2015 |
December 2018 |
December 2020 |
December 15, 2015 |
April 19, 2018 |
|
- Arkansas Children's Hospital
Little Rock, Arkansas, United States - Rady Children's Hospital
San Diego, California, United States - Connecticut Children's Hospital
Hartford, Connecticut, United States - (and 6 more...)
|
| 22 |
NCT02864563 |
Recruiting |
Pan-genome Analysis of Neuroblastoma by Comparative Genomic Hybridization and Correlation With Pathology for the Diagnostic and the Prognostic Classification |
|
- Procedure: Blood sampling
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Progression-Free survival
- Progression at metastatic location-Free survival
- Overall-Free survival
|
500 |
All |
up to 18 Years (Child, Adult) |
NCT02864563 |
IC 2007-09 |
PHRCNB07 |
October 2008 |
December 2021 |
June 2022 |
August 12, 2016 |
April 6, 2018 |
|
- Hôpital Nord Amiens
Amiens, France - Chu Angers
Angers, France - Chr R.Pellegrin
Bordeaux, France - (and 24 more...)
|
| 23 |
NCT02914405 |
Not yet recruiting |
Phase I Study of Investigational Medicinal Products in Children With Relapsed/Refractory Neuroblastoma |
|
- Drug: Nivolumab
- Drug: Ch14.18/CHO
|
Interventional |
Phase 1 |
- University Hospital Southampton NHS Foundation Trust
- University College London Hospitals NHS Foundation Trust
- University of Wisconsin, Madison
- (and 4 more...)
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of Treatment-Emergent Adverse Events [Safety and tolerability] of 131-I-MIBG, ch14.18/CHO and Nivolumab in paediatric patients
- Anti-tumour response in patients with measureable disease as measured by immunocytology, MIBG, CT and/or MRI in patients receiving 131-I-MIBG, ch14.18/CHO and Nivolumab in patients with relapsed and refractory high risk neuroblastoma
- KIR/KIR-Ligand genotype, FcγR genotype
|
36 |
All |
1 Year to 18 Years (Child, Adult) |
NCT02914405 |
RHM CHI0811
2016-002221-11 |
Inbraced |
May 2018 |
May 2020 |
May 2020 |
September 26, 2016 |
April 18, 2018 |
|
|
| 24 |
NCT02786719 |
Recruiting |
A Study of High Risk Induction Chemotherapy for Neuroblastoma Without Prophylactic Administration of Myeloid Growth Factors |
|
- Drug: Topotecan
- Drug: Cyclophosphamide
- Drug: Cisplatin
- (and 4 more...)
|
Interventional |
Not Applicable |
- Baylor College of Medicine
- Texas Children's Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- the incidence of infections in chemotherapy cycles NOT followed by hematopoietic growth factors
- incidence of delay in chemotherapy administration due to prolonged neutrophil recovery
- the number of antibiotic days and hospital days due to fever and/or infection
- (and 2 more...)
|
13 |
All |
12 Months to 18 Years (Child, Adult) |
NCT02786719 |
H-38179 (SPRING)
SPRING |
SPRING |
June 2016 |
December 2018 |
June 2019 |
June 1, 2016 |
February 22, 2018 |
|
- Rady Children's Hospital
San Diego, California, United States - Texas Children's Hospital
Houston, Texas, United States
|
| 25 |
NCT02337309 |
Recruiting |
SF1126 for Patients With Relapsed or Refractory Neuroblastoma |
|
|
Interventional |
Phase 1 |
- New Approaches to Neuroblastoma Therapy Consortium
- SignalRX Pharmaceuticals, Inc.
- University of Southern California
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Toxicities, based on the CTCAE criteria, will be used to measure the severity of adverse events
- Evaluation of response
- Pharmacokinetics: Parameters include AUC, clearance, Cmax, Tmax, & terminal half-life for SF1101 & SF1174. With rapid conversion of SF1126 to SF1101, only AUC, clearance, Cmax & Tmax are calculated for SF1126.
|
28 |
All |
1 Year to 30 Years (Child, Adult) |
NCT02337309 |
NANT 2014-01
N14-01
R01FD005740 |
|
July 2015 |
December 2018 |
June 2019 |
January 13, 2015 |
January 19, 2018 |
|
- Children's Hospital Los Angeles
Los Angeles, California, United States - Lucille Salter Packer Children's Hospital, Stanford University
Palo Alto, California, United States - UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States - (and 9 more...)
|
| 26 |
NCT01587300 |
Recruiting |
Neuroblastoma Biology Study |
|
|
Observational |
|
- New Approaches to Neuroblastoma Therapy Consortium
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
|
500 |
All |
up to 99 Years (Child, Adult, Senior) |
NCT01587300 |
N2004-05 |
|
July 2011 |
December 2018 |
June 2019 |
April 30, 2012 |
January 19, 2018 |
|
- Children's Hospital Los Angeles
Los Angeles, California, United States - Lucille Salter Packer Children's Hospital, Stanford University
Palo Alto, California, United States - UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States - (and 11 more...)
|
| 27 |
NCT02559778 |
Recruiting |
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy |
|
- Drug: bortezomib
- Drug: crizotinib
- Drug: dasatinib
- (and 4 more...)
|
Interventional |
Phase 2 |
- Giselle Sholler
- Dell, Inc.
- Beat NB Cancer Foundation
- (and 2 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of subjects that have a targeted agent chosen for treatment.
- Number of subjects that receive 75% of dosing of medications while on study protocol during cycles 3-6.
- Number of subjects required to go off therapy due to treatment-related adverse events as assessed by CTCAE v4.0.
- (and 4 more...)
|
500 |
All |
12 Months to 21 Years (Child, Adult) |
NCT02559778 |
NMTRC012 |
PEDS-PLAN |
September 2015 |
September 2025 |
September 2026 |
September 24, 2015 |
February 15, 2018 |
|
- University of Alabama, Children's of Alabama
Birmingham, Alabama, United States - Phoenix Children's Hospital
Phoenix, Arizona, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 20 more...)
|
| 28 |
NCT02558244 |
Recruiting |
Impact of Image-defined Risk Factors on the Outcome of Patients With Neuroblastoma: A Retrospective Study |
|
|
Observational |
|
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Overall survival (OS)
- Event Free Survival (EFS)
- Complications of Surgery
|
100 |
All |
up to 18 Years (Child, Adult) |
NCT02558244 |
Image-defined RF NB |
|
January 2016 |
September 2018 |
October 2018 |
September 23, 2015 |
December 28, 2017 |
|
- Assiut University
Assiut, Egypt
|
| 29 |
NCT01583842 |
Recruiting |
124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study |
|
- Radiation: 124I-MIBG (no-carrier added)
- Radiation: 124I-MIBG (carrier added)
|
Interventional |
Not Applicable |
- Katherine Matthay
- University of California, San Francisco
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Measurements of organ dosimetry using high specific activity (no carrier added) 124I-MIBG PET/CT in patients with refractory or relapsed neuroblastoma
- Measurements of organ dosimetry using low specific activity (carrier added) 124I-MIBG PET/CT in patients with refractory or relapsed neuroblastoma
- Change from baseline of blood pressure measurements at week 7.
- (and 5 more...)
|
20 |
All |
3 Years and older (Child, Adult, Senior) |
NCT01583842 |
12088 |
|
June 2012 |
December 2017 |
December 2018 |
April 24, 2012 |
December 11, 2017 |
|
- University of California, San Francisco
San Francisco, California, United States
|
| 30 |
NCT02245997 |
Recruiting |
Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma |
|
- Radiation: External beam radiotherapy
|
Interventional |
Not Applicable |
- Memorial Sloan Kettering Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- assess local control rates treatment response
- event-free survival
- Assessment of toxicity
|
50 |
All |
12 Months to 18 Years (Child, Adult) |
NCT02245997 |
14-186 |
|
September 2014 |
September 2018 |
September 2018 |
September 22, 2014 |
November 8, 2017 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
| 31 |
NCT02771743 |
Recruiting |
Response-based Treatment of High-risk Neuroblastoma |
- Newly Diagnosed High Risk Neuroblastoma
|
- Drug: Cisplatin
- Drug: Doxorubicin
- Drug: Etoposide
- (and 8 more...)
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of event free survival
- Rate of late adverse effects
|
54 |
All |
Child, Adult, Senior |
NCT02771743 |
2015-02-064 |
|
April 2015 |
March 2020 |
March 2023 |
May 13, 2016 |
May 24, 2016 |
|
- Samsung Medical Center
Seoul, Korea, Republic of
|
| 32 |
NCT02100930 |
Recruiting |
Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma |
|
- Biological: Anti-GD2 3F8 Monoclonal Antibody
- Drug: GM-CSF (granulocyte-macrophage colony-stimulating factor)
- Drug: oral isotretinoin
|
Interventional |
Not Applicable |
- Memorial Sloan Kettering Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- relapse-free survival
- complete remission
|
125 |
All |
Child, Adult, Senior |
NCT02100930 |
13-260 |
|
March 2014 |
March 2019 |
March 2019 |
April 1, 2014 |
April 10, 2018 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
| 33 |
NCT02308527 |
Recruiting |
Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children |
|
- Drug: Bevacizumab
- Drug: Temozolomide
- Drug: Irinotecan
- Drug: Topotecan
|
Interventional |
Phase 2 |
- University of Birmingham
- Cancer Research UK
- Roche Pharma AG
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Best response (Complete Response or Partial Response) while on trial treatment, within 18 or 24 weeks depending on the arm of the trial participant is randomised to.
- To evaluate the toxicity of the regimens
- To evaluate the safety of the regimens
- To evaluate the overall safety of the regimens
|
160 |
All |
1 Year to 21 Years (Child, Adult) |
NCT02308527 |
RG_11-087
2012-000072-42 |
BEACON |
July 2013 |
July 2018 |
January 2022 |
December 4, 2014 |
May 9, 2017 |
|
- St Anna Children's Hospital and CCRI/Studies and Statistics
Vienna, Austria - University Hospital Rigshospitalet
Copenhagen, Denmark - Hopital des Enfants
Toulouse, France - (and 5 more...)
|
| 34 |
NCT03406273 |
Recruiting |
Standardized Protocol of Surgery and Radiation for Patients With Brain Metastases in Relapsed Neuroblastoma |
|
- Radiation: Cerebral Spinal (CS) radiation
- Radiation: Focal radiotherapy (SRS)
|
Interventional |
Not Applicable |
- Giselle Sholler
- Spectrum Health Hospitals
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate (ORR) of Participants by the presence of radiologically measurable CNS disease by cross-sectional CT or MRI imaging and/or by MIBG or PET scans and/or CSF Sampling.
- Number of Participants with Adverse Events as a Measure of Safety
- Progression Free Survival (PFS) interval for CNS lesions will be measured by days from start of treatment (surgery/radiation) to the date of any future progressive disease (PD) in CNS lesions per RESIST criteria.
- Length of time that participants experience Overall Survival (OS)
|
20 |
All |
up to 21 Years (Child, Adult) |
NCT03406273 |
HITC001 |
|
June 1, 2018 |
January 1, 2022 |
January 1, 2023 |
January 23, 2018 |
April 17, 2018 |
|
- Helen DeVos Children's Hospital
Grand Rapids, Michigan, United States
|
| 35 |
NCT01370330 |
Available |
131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol |
|
- Drug: Metaiodobenzylguanidine (MIBG)
|
Expanded Access |
|
- University of California, San Francisco
|
Other |
|
|
|
All |
1 Year and older (Child, Adult, Senior) |
NCT01370330 |
CompUse MIBG |
|
|
|
|
June 9, 2011 |
November 9, 2017 |
|
- University of California, San Francisco
San Francisco, California, United States
|
| 36 |
NCT01728155 |
Recruiting |
European Low and Intermediate Risk Neuroblastoma Protocol |
- LOW AND INTERMEDIATE PAEDIATRIC NEUROBLASTOMA AND NEONATAL SUPRARENAL MASSES
|
|
Interventional |
Phase 3 |
- Instituto de Investigacion Sanitaria La Fe
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Primary aim for Low Risk Neuroblastoma
- Primary aim for Intermediate Risk Neuroblastoma
- Primary Aim for Neonatal Suprarenal Masses
- (and 17 more...)
|
685 |
All |
90 Days to 18 Years (Child, Adult) |
NCT01728155 |
LINES |
|
December 2011 |
December 2021 |
December 2031 |
November 16, 2012 |
June 19, 2017 |
|
- PHO Med Uni Graz
Graz, Austria - Department Kinder- und Jugendheilkunde
Innsbruck, Austria - Landes-Frauen- und Kinderklinik Linz
Linz, Austria - (and 84 more...)
|
| 37 |
NCT03189706 |
Recruiting |
Pilot Study of Chemoimmunotherapy for High-Risk Neuroblastoma |
|
- Drug: Irinotecan
- Drug: temozolomide
- Biological: Hu3F8
- Drug: GM-CSF
|
Interventional |
Early Phase 1 |
- Memorial Sloan Kettering Cancer Center
- Y-Mabs, Inc
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
|
10 |
All |
Child, Adult, Senior |
NCT03189706 |
17-251 |
|
June 12, 2017 |
June 2019 |
June 2019 |
June 16, 2017 |
July 21, 2017 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
| 38 |
NCT01526603 |
Recruiting |
High Dose Chemotherapy and Autologous Transplant for Neuroblastoma |
|
- Drug: Carboplatin
- Biological: Autologous stem cell infusion
- Biological: Granulocyte colony stimulating factor
- (and 4 more...)
|
Interventional |
Not Applicable |
- Masonic Cancer Center, University of Minnesota
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Patients with Successful Engraftment
- Number of Patients with Disease Free Survival
- Overall Survival
- Number of Patients with Treatment Related Death
|
20 |
All |
up to 30 Years (Child, Adult) |
NCT01526603 |
2011OC072
MT2011-11C |
|
March 28, 2012 |
February 2019 |
February 2020 |
February 6, 2012 |
March 23, 2018 |
|
- Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, United States
|
| 39 |
NCT01757626 |
Recruiting |
Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma |
|
- Biological: Hu3F8 With GM-CSF
|
Interventional |
Phase 1
Phase 2 |
- Memorial Sloan Kettering Cancer Center
- Y-mAbs Therapeutics
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- maximum tolerated dosage
- assess the toxicity
- pharmacokinetics of hu3F8
- (and 2 more...)
|
224 |
All |
1 Year and older (Child, Adult, Senior) |
NCT01757626 |
12-230 |
|
December 2012 |
December 2021 |
December 2021 |
December 31, 2012 |
April 18, 2018 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
| 40 |
NCT02139397 |
Recruiting |
Study of DFMO in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma |
|
- Drug: DFMO
- Drug: Bortezomib
|
Interventional |
Phase 1
Phase 2 |
- Giselle Sholler
- Beat NB Cancer Foundation
- Because of Ezra
- Spectrum Health Hospitals
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability
- Determine the Overall Response Rate (ORR) of Participants using RECIST criteria
- Determine the Progression Free Survival (PFS) of Participants using days until progression
- (and 3 more...)
|
38 |
All |
up to 21 Years (Child, Adult) |
NCT02139397 |
NMTRC010 |
|
May 2014 |
May 2018 |
May 2018 |
May 15, 2014 |
April 26, 2017 |
|
- Arkansas Children's Hospital
Little Rock, Arkansas, United States - Connecticut Children's Hospital
Hartford, Connecticut, United States - Arnold Palmer Hospital for Children- MD Anderson
Orlando, Florida, United States - (and 3 more...)
|
| 41 |
NCT01419834 |
Recruiting |
Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors |
|
- Biological: Humanized 3F8 Monoclonal Antibody (Hu3F8)
|
Interventional |
Phase 1 |
- Memorial Sloan Kettering Cancer Center
- Band of Parents
- Y-mAbs Therapeutics
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- maximum tolerated dosage (MTD)
- pharmacokinetics of hu3F8
- To assess activity of hu3F8 against NB and other GD2-positive tumors.
- To quantitate pain during hu3F8 treatment
|
74 |
All |
2 Years and older (Child, Adult, Senior) |
NCT01419834 |
11-009 |
|
August 2011 |
August 2018 |
August 2018 |
August 18, 2011 |
December 27, 2017 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
| 42 |
NCT01467986 |
Recruiting |
Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma |
|
- Drug: Dasatinib
- Drug: Rapamycin
- Drug: Irinotecan
- Drug: Temozolomide
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary endpoint is progression-free survival (PFS)
- Overall survival (OS)
- Response to the investigational treatment after 4 and 8 courses of I/T and 1-year-follow-up in the RIST treatment arm
- (and 6 more...)
|
114 |
All |
up to 25 Years (Child, Adult) |
NCT01467986 |
RIST-rNB-2011 |
RIST-rNB-2011 |
August 2013 |
September 2018 |
December 2018 |
November 9, 2011 |
December 30, 2016 |
|
- University Hospital Regensburg, Department of Pediatric Hematology and Oncology
Regensburg, Germany
|
| 43 |
NCT00911560 |
Recruiting |
Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma |
|
- Biological: adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH
|
Interventional |
Phase 1
Phase 2 |
- Memorial Sloan Kettering Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine the maximally tolerated dose of OPT-821 in a vaccine containing two antigens abundantly expressed on neuroblastoma. (PHASE I)
- To improve event-free survival (EFS) of patients who are in first or second (or later) complete/very good partial remission (CR/VGPR), i.e., have no evidence of NB by standard studies. (PHASE II)
- To assess anti-NB activity of the bivalent vaccine plus oral β-glucan in patients who are enrolled with evidence of minimal residual disease (MRD) by molecular biological testing of bone marrow. (PHASE II)
- (and 4 more...)
|
215 |
All |
up to 21 Years (Child, Adult) |
NCT00911560 |
05-075 |
|
May 2009 |
May 2020 |
May 2020 |
June 2, 2009 |
January 19, 2018 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
| 44 |
NCT02043899 |
Recruiting |
A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma |
- Metastatic Neuroblastoma (Stage 4 on International Neuroblastoma Staging System (INSS))
|
- Drug: [124I]meta-Iodobenzylguanidine
|
Interventional |
Phase 1
Phase 2 |
|
Other |
- Primary Purpose: Treatment
|
- Comparison of the percentage of lesions detected as positive by [123I]mIBG planar scintigraphy which are also considered positive with [124I]mIBG PET/CT
- Assessing the safety and toxicity profile of a single intravenous administration of [124I]mIBG
|
33 |
All |
1 Year and older (Child, Adult, Senior) |
NCT02043899 |
CRUKD/12/002 |
|
February 2014 |
July 2019 |
July 2019 |
January 23, 2014 |
February 2, 2018 |
|
- University College London Hospital
London, United Kingdom - Royal Marsden Hospital
Sutton, United Kingdom
|
| 45 |
NCT03165292 |
Not yet recruiting |
Trial Evaluating and Comparing Two Intensification Treatment Strategies for Metastatic Neuroblastoma Patients With a Poor Response to Induction Chemotherapy |
- Very High Risk Neuroblastoma
|
- Radiation: 131I- mIBG
- Drug: Topotecan
- Drug: Thiotepa
- Procedure: Autologous stem cell transplant
|
Interventional |
Phase 2 |
- Gustave Roussy, Cancer Campus, Grand Paris
- SIOPEN
- French National Cancer Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event Free Survival (EFS)
|
150 |
All |
Child, Adult, Senior |
NCT03165292 |
2015-003130-27
2015/2294 |
VERITAS |
September 2017 |
June 2023 |
June 2025 |
May 24, 2017 |
July 11, 2017 |
|
- Gustave Roussy
Villejuif, Val de Marne, France
|
| 46 |
NCT02780128 |
Recruiting |
Next Generation Personalized Neuroblastoma Therapy |
|
- Procedure: Biopsy
- Drug: Ceritinib
- Drug: Trametinib
- (and 13 more...)
|
Interventional |
Phase 1 |
- Yael P Mosse
- Novartis Pharmaceuticals
- Foundation Medicine
- Children's Hospital of Philadelphia
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of dose limiting toxicities when combining ceritinib combined with ribociclib
- Adverse events of trametinib as characterized and graded by CTCAE V4.03
- Incidence of dose limiting toxicities of HDM201
- (and 4 more...)
|
94 |
All |
1 Year to 21 Years (Child, Adult) |
NCT02780128 |
14-011071 |
NEPENTHE |
July 2016 |
May 2018 |
May 2026 |
May 23, 2016 |
February 1, 2018 |
|
- The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
|
| 47 |
NCT02765243 |
Recruiting |
Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma |
- Neuroblastoma
- Effects of Immunotherapy
|
- Biological: Anti-GD2 CART
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of patients with adverse events.
- Anti-tumor effects
- To evaluate the expansion and persistence of anti-GD2 CAR T cells
- Survival time of the patients
|
30 |
All |
1 Year to 14 Years (Child) |
NCT02765243 |
2016-EKZX-001 |
4SCAR-GD2 |
May 1, 2016 |
May 12, 2019 |
December 30, 2019 |
May 6, 2016 |
December 19, 2017 |
|
- Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
|
| 48 |
NCT02112617 |
Recruiting |
Phase II Study of Proton Radiation Therapy for Neuroblastoma |
- Neuroblastoma
- Ganglioneuroblastoma
|
- Radiation: Proton Beam Radiation Therapy
|
Interventional |
Not Applicable |
- Massachusetts General Hospital
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Describe late complications of radiation therapy delivered with proton radiotherapy in place of photon radiation for patients with neuroblastoma
- To evaluate acute and subacute toxicities of proton radiotherapy in place of photon radiation for patients with neuroblastoma.
- Progression free survival
- Overall survival rates
|
30 |
All |
6 Months to 25 Years (Child, Adult) |
NCT02112617 |
13-443 |
|
June 2014 |
March 2024 |
March 2028 |
April 14, 2014 |
January 19, 2018 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 49 |
NCT01850888 |
Recruiting |
MIBG for Refractory Neuroblastoma and Pheochromocytoma |
- Relapsed Neuroblastoma
- Metastatic Pheochromocytoma
|
- Drug: 131 I-Metaiodobenzylguanidine (131I-MIBG)
- Drug: Potassium iodide solution
- Drug: G-CSF
- Procedure: hematopoietic stem cell infusion
|
Interventional |
Not Applicable |
- Masonic Cancer Center, University of Minnesota
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of patients who receive 131 I-MIBG.
- Disease response
- Incidence of hematologic toxicities
- (and 4 more...)
|
100 |
All |
1 Year and older (Child, Adult, Senior) |
NCT01850888 |
2012LS107 |
|
December 2013 |
December 2018 |
December 2018 |
May 10, 2013 |
December 5, 2017 |
|
- University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota, United States
|
| 50 |
NCT02650648 |
Recruiting |
Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma |
|
- Drug: cyclophosphamide
- Biological: NK cells
- Biological: hu3F8
- Drug: rIL-2
|
Interventional |
Phase 1 |
- Memorial Sloan Kettering Cancer Center
- Y-mAbs Therapeutics
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The number patient responses observed at each dose level
|
36 |
All |
Child, Adult, Senior |
NCT02650648 |
15-272
5415 |
|
January 2016 |
January 2021 |
January 2021 |
January 8, 2016 |
December 27, 2017 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
Create an RSS feed from your search for:
Download the search results for: